Have you ever thought about taking part in a Medical Trial? By registering your details with MedTrials.co.uk, we are able to send your details directly to companies who are looking for volunteers to take part in their medical research studies.
Information about you is kept on a register that CROs, Pharmaceutical companies and Clinical Investigators can access to contact you regarding individual studies.
MedTrials.co.uk is a website that will put you in direct contact with Pharmaceutical Companies, CRO’s (Clinical Research Organisations) and Clinical Investigators that are running Phase I (1) and Phase II (2) clinical trials.
Medical trials are an integral part of the drug development process. Patient and volunteer participation is vital for continued medical research and these trials are carried out under strict regulations.
If at any point you feel that you have changed your mind and are no longer interested in undertaking a medical trial you can unsubscribe from our service. If you are already part way through a medical trial, speak to the Clinical Investigator and they will advise you of your options.
Clinical research companies often offer financial compensation for your time and expenses.
Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine… Go to Source
The schedule 1 classification of LSD, psilocybin and other psychedelics makes research into their potential therapeutic benefits almost impossible, argues one expert. Go to Source
Amgen has announced the publication of primary results from the Phase 3 OPTiM study in the Journal of Clinical Oncology (JCO). Go to Source
Researchers are looking at whether aspirin can improve the healing rates of leg ulcers in older adults. Go to Source
Women who choose not to participate in a clinical trial may be significantly more likely to later regret that decision than women who choose to participate in the study, according to a team of Penn… Go to Source
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that a Phase 3 study of sarilumab, an investigational, fully-human IL6 receptor antibody, met its co-primary efficacy endpoints of a… Go to Source